Page last updated: 2024-12-06
iopydone
Description
Iopydone is a contrast agent used in X-ray imaging, particularly in cholangiography. It is a derivative of iodized fatty acids, specifically a triiodinated derivative of poppyseed oil. Iopydone is administered intravenously or directly into the biliary tract. It works by increasing the density of the bile ducts and gallbladder, making them more visible on X-ray images. This allows for better visualization of these structures, helping in the diagnosis of various conditions such as gallstones, cholecystitis, and bile duct strictures. Research on iopydone primarily focuses on its efficacy, safety, and potential adverse effects. Studies have explored its use in various clinical settings, including the diagnosis of biliary tract diseases, evaluation of liver function, and assessment of pancreatic duct anatomy. The compound is also studied for its potential interactions with other drugs and its effects on different patient populations, including pregnant women and individuals with specific medical conditions.'
iopydone: minor descriptor (75-80); on-line & Index Medicus search IODOPYRIDONES (68-80) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 21752 |
| CHEMBL ID | 2104367 |
| SCHEMBL ID | 666661 |
| MeSH ID | M0086937 |
Synonyms (66)
| Synonym |
|---|
| brn 1447538 |
| iopidona [inn-spanish] |
| 4(1h)-pyridone, 3,5-diiodo- |
| nsc 135284 |
| hytrast (van) |
| 4(1h)-pyridinone, 3,5-diiodo- |
| iopydone [usan:inn:ban:jan] |
| jopydonum |
| einecs 226-969-1 |
| iopydonum [inn-latin] |
| 4(1h)-pyridone,5-diiodo- |
| iopydone |
| wln: t6m dvj ci ei |
| DJP , |
| 3,5-diiodo-4-pyridone |
| 5579-93-1 |
| 3,5-diiodo-4(1h)-pyridone |
| nsc-135284 |
| component of hytrast |
| 4(1h)-pyridinone,5-diiodo- |
| iopydon |
| hytrast |
| nsc135284 |
| 3,5-diiodo-4-pyridinol |
| AC-907/25014036 |
| 3,5-diiodopyridin-4(1h)-one |
| 7153-08-4 |
| nsc-60547 |
| nsc60547 |
| 4-pyridinol,5-diiodo- |
| 3,5-diiodo-1h-pyridin-4-one |
| D04587 |
| iopydone (usan) |
| 3,5-diiodo-4-hydroxypyridine |
| AKOS000631308 |
| iopidona |
| unii-j6b56xb19t |
| iopydonum |
| j6b56xb19t , |
| AKOS015899046 |
| CHEMBL2104367 |
| iopydone [mart.] |
| iopydone [inn] |
| iopydone [who-dd] |
| iopydone [mi] |
| iopydone [usan] |
| SCHEMBL666661 |
| 3,5-diiodopyridin-4-ol |
| DTXSID9063954 |
| 3,5-diiodo-4-hydrox-ypyridine |
| smr002530268 |
| MLS006011639 |
| 4-pyridinol, 3,5-diiodo- |
| component of hytrast (salt/mix) |
| 3,5-diiodo-4(1h)-pyridinone |
| mfcd00023554 |
| W12571 |
| W18704 |
| CS-0036290 |
| SY040052 |
| FT-0762575 |
| AS-20011 |
| 4-hydroxy-3,5-diiodopyridine |
| Q27281264 |
| A917903 |
| EN300-109702 |
Research Excerpts
Toxicity
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 14 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 2 (13.33%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (86.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |